Andrew Combs - 15 Feb 2022 Form 4 Insider Report for Prelude Therapeutics Inc (PRLD)

Role
EVP, Head of Chemistry
Signature
/s/ Laurent Chardonnet, Attorney-in-Fact
Issuer symbol
PRLD
Transactions as of
15 Feb 2022
Net transactions value
$0
Form type
4
Filing time
17 Feb 2022, 18:07:19 UTC
Previous filing
15 Dec 2021
Next filing
04 Apr 2022
SEC
View on sec.gov

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction PRLD Employee Stock Option (right to buy) Award $0 +100,000 $0.000000 100,000 15 Feb 2022 Common Stock 100,000 $10.58 Direct F1
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 The stock option vests as to 25% of the total shares on February 15, 2023, and thereafter vests as to 1/48 of the total shares monthly until fully vested, subject to the Reporting Person's provision of service to the Issuer on each vesting date.